CNBX Pharmaceuticals, Inc. is a development-stage company specializing in the research, development and commercialization of cannabinoid-based pharmaceutical and wellness products. Founded in 2017 and headquartered in New York, CNBX has focused its early efforts on creating transdermal delivery systems that harness the therapeutic potential of cannabinoids to address pain, inflammation and various dermatological conditions. Through proprietary formulations and collaboration with academic and contract research organizations, the company aims to bring novel, science-backed therapies to market for patients seeking non-opioid alternatives.
The company’s lead product candidate, CT-3, is a topical transdermal cream designed to deliver cannabinoids directly to targeted areas for relief from sustained musculoskeletal pain. CNBX’s pipeline also includes formulations intended for neuropathic pain management and treatment of chronic skin conditions such as atopic dermatitis. Each product leverages the company’s patented transdermal technology platform, which is engineered to enhance skin penetration and optimize the controlled release of active ingredients over time.
CNBX Pharmaceuticals operates primarily in North America, with strategic partnerships in Europe aimed at expanding its distribution footprint. The company works in compliance with regulatory standards set by the U.S. Food and Drug Administration, Health Canada and relevant European authorities. Its commercial strategy encompasses direct-to-pharmacy programs, e-commerce channels and collaborations with established distributors to facilitate market access for both prescription and over-the-counter applications.
The executive team at CNBX is led by a seasoned management group with deep expertise in pharmaceutical R&D, regulatory affairs and commercial operations. The scientific advisory board comprises experts in pharmacology, cannabinoid science and clinical development, guiding the company’s efforts to advance its product candidates through preclinical and clinical stages. With a focus on drug safety, efficacy and quality manufacturing, CNBX Pharmaceuticals is positioned to address unmet medical needs through innovative cannabinoid therapies.
AI Generated. May Contain Errors.
Free CNBX Stock Alerts